Quantum BioPharma Ltd. (NASDAQ: QNTM) has drawn national media attention after its alcohol recovery formulation, Unbuzzd, was examined in a Men's Fitness article by Lakshan Weeraratne. The coverage, first announced via NEWMEDIAWIRE, focuses on clinical trial results that suggest the product may accelerate alcohol metabolism and reduce certain hangover symptoms, while also emphasizing important study limitations.
The article details findings from a company-sponsored, placebo-controlled study involving 26 healthy adults, with 24 participants completing both treatment sessions. Researchers reported significantly lower estimated blood alcohol concentrations at several time points, improved self-rated alertness, and reduced headache severity on certain assessments. Among 17 participants identified as rapid responders, the average percentage decline in estimated blood alcohol during the first 30 minutes was 40.7% greater with Unbuzzd than with placebo. These results, as covered in the Men’s Fitness article by Lakshan Weeraratne, suggest a potential role for the formulation in speeding alcohol clearance for some individuals.
However, the Men's Fitness piece also emphasized the study's limitations, including its small sample size, company sponsorship, and mixed results across broader measures of hangover severity and cognitive impairment. The article noted that larger, independent clinical trials are needed to confirm the findings, and it cautioned that increased alertness does not indicate sobriety or fitness to drive. For readers, this means that while the early data are encouraging, they should not interpret the product as a way to safely consume alcohol and drive or as a guaranteed hangover cure.
The media coverage matters for investors and the broader biopharmaceutical industry because it brings scrutiny to a product that represents a significant royalty stream for Quantum BioPharma. The company invented UNBUZZD(TM) and spun out its over-the-counter version to Unbuzzd Wellness Inc., retaining a 19.84% ownership stake as of March 31, 2026. The agreement includes royalty payments of 7% of sales until payments to Quantum total $250 million, after which the royalty drops to 3% in perpetuity. Quantum also retains 100% of the rights to develop similar products or alternative formulations specifically for pharmaceutical and medical uses. As the Quantum BioPharma (NASDAQ: QNTM) profile notes, the company is dedicated to building a portfolio of innovative assets for neurodegenerative and metabolic disorders and alcohol misuse disorders.
Beyond Unbuzzd, Quantum's lead compound, Lucid-MS, is a patented new chemical entity shown in preclinical models to prevent and reverse myelin degradation, the underlying mechanism of multiple sclerosis. The dual focus on a consumer-facing alcohol recovery product and a serious drug candidate for MS illustrates the company's strategy of blending near-term revenue potential with long-term biotech development. For industry observers, the Men's Fitness coverage serves as a reminder that early-stage clinical results—especially those from small, company-sponsored studies—warrant cautious interpretation until replicated in independent research.
The full original release can be viewed at www.newmediawire.com.
